1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Procter & Gamble Health Limited

Procter & Gamble Health Limited

PGHL.NS
Procter & Gamble Health LimitedIN flagNational Stock Exchange of India
6,867.00
INR
+28.00
- -
113.99BMarket Cap
Procter & Gamble Health Limited
PGHL.NS
(National Stock Exchange of India)

Recent

price

6,867.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2021
2022
2023
2024
2026
TTM
FRC
282.1
306.69
333.52
413.05
478.31
519.84
564.82
597.95
420.58
492.9
558.21
596.88
657.88
726.45
680.44
- -
848.99
Revenue per Share
39.04
38.06
38.36
47.23
33.66
26.04
32.27
47.67
56.57
505.27
95.64
106.51
115.98
138.24
121.08
- -
197.12
Basic EPS, GAAP
19.19
34.45
2.25
24.49
-19.86
-21.34
23.06
45.42
14.07
-94.65
91.12
117.28
79.28
116.58
124.44
- -
- -
Free Cash Flow per Basic Share
17.57
114.43
- -
- -
2.5
8.57
5.98
7.5
11
15.04
439.31
230
171
56.5
250
- -
- -
Dividend per Share
9.9
10
50.55
90.15
110.5
126.74
152.44
185.72
227.55
713.62
10
207.42
152.82
233.45
104.93
- -
10.01
Book Value per Share
278.63
208.69
246.9
291.29
314.93
333.81
361.97
399.8
441.26
927.55
491.87
423.87
371.37
451.79
323.67
- -
316.02
Tangible Book Value per Share
17
17
17
17
17
17
17
17
17
17
17
17
17
17
17
- -
17
Basic Weighted Avg Shares
4,731
5,091
5,536
6,856
7,940
8,629
9,376
9,926
6,981
8,182
9,266
9,908
10,920
12,059
11,295
14,080
14,080
Sales/Revenue/Turnover
20.39
18.81
16.12
14.17
8.57
5.4
10.59
13.3
18.52
15.62
20.12
22.72
22.69
24.53
24.71
30.76
30.76
Operating Margin (%)
75
71
80
89
101
127
234
248
264
250
172
300
271
281
274
236
236
Depreciation Expense
655
632
637
784
559
432
536
791
939
8,387
1,588
1,768
1,925
2,295
2,010
3,269
3,269
Net Income, GAAP
32.11
33.99
33.38
32.87
36.68
35.07
35.73
31.3
38.27
35.6
32.26
24.21
24.02
26.97
26.47
27.33
27.33
Effective Tax Rate (%)
13.84
12.41
11.5
11.43
7.04
5.01
5.71
7.97
13.45
102.51
17.13
17.84
17.63
19.03
17.79
23.22
23.22
Profit Margin (%)
3,816
2,715
3,029
3,614
3,658
3,634
4,140
4,497
5,271
13,415
6,229
4,882
3,761
4,922
3,053
3,013
3,013
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
29
- -
89
69
57
57
LT Debt
4,673
3,464
4,101
4,837
5,230
5,543
6,010
6,638
7,333
15,401
8,168
7,037
6,165
7,509
5,382
5,246
5,246
Total Equity
14.26
15.54
15.75
14.6
8.49
5.55
11.02
14.3
11.2
7.03
10.39
21.76
27.81
30.74
30.89
57.32
57.71
Return on Invested Capital (%)
391.51
380.88
126.74
67.13
33.55
21.95
22.98
27.63
26.78
106.47
26.29
96.28
63.39
70.13
69.1
312.29
1,306.36
Return on Capital (%)
391.39
380.6
126.71
67.13
33.55
21.95
23.12
28.19
27.38
107.37
26.43
97.98
64.39
71.58
71.56
342.73
1,969.34
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
28
- -
36
LT Borrowings
- -
- -
- -
LT Finance Leases
34
- -
57
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
- -
17
Market Capitalization
104,600
94,576
79,583

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
6,393
- -
5,563
Cash, Cash Equivalents & STI
3,021
- -
2,015
Accounts Receivable, Net
1,375
- -
1,643
Inventories
1,273
- -
1,366
Total Current Liabilities
2,225
- -
2,549
Payables & Accruals
- -
- -
- -
ST Debt
28
- -
36
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.71%
-7.06%
-2.54%
Free Cash Flow
-104.28%
21.23%
56.02%
Net Income, GAAP
89.21%
17.94%
62.66%
Sales/Revenue/Turnover
6.12%
9.18%
24.66%
Total Cash Common Dividend
308.33%
36.84%
-18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,049
3,100
2,525
2,621
11,295
2026
3,249
3,739
3,704
3,387
14,080

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39.5
43.42
28
- -
121.08
2026
53.54
46.74
56.99
39.87
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
250
2026
- -
- -
- -
- -
- -
Similar Companies
Hanmi Pharm. Co., Ltd. (128940.KS)
Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
Tasly Pharmaceutical Group Co., Ltd (600535.SS)
High Fusion Inc. (2NU.F)
China Shineway Pharmaceutical Group Limited (CSWYY)
Hemp, Inc (HEMP)
Business
Procter & Gamble Health Limited manufactures and markets over-the-counter healthcare products, vitamins, minerals, and supplements in India; its core brands include Evion (Vitamin E), Neurobion (Vitamin B-complex for nerve health), Polybion (Vitamin B-complex), Seven Seas (cod liver oil supplements), Nasivion (nasal decongestants), Livogen (iron supplements for anemia), and Cosome (cough relief); the company operates a GMP-certified manufacturing facility in Usgaon, Goa, with capacity for over 260 million ampoules and 744 million softgel capsules annually, exporting to 13 countries. Founded in 1967 as a Merck subsidiary and headquartered in Mumbai, India, it changed its name from Merck Limited to Procter & Gamble Health Limited in May 2019 following P&G's acquisition of Merck's Consumer Health business in December 2018, with Procter & Gamble Overseas India B.V. holding 51.81% ownership. The company primarily serves consumers through distributors, pharmacies, chemists, and healthcare professionals in India, with additional exports to Sri Lanka, Nepal, Myanmar, and Maldives. Recent developments include revised maximum retail prices effective September 22, 2025, due to GST rate changes; strong Q2 fiscal 2026 results with sales of Rs 319 crore (up 3% YoY) and profit after tax of Rs 89 crore (up 8% YoY) as of September 30, 2025; and shareholder approval in November 2025 for appointing Shashank Srowthy as an Executive Director.